fullscreen

eFinder

eFinder

Home › Patient Outcomes › Article

Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Cnbc · · 802 words · By Angelica Peebles
Patient Outcomes Pharmaceutical Market Value Medical Breakthrough
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Patient Outcomes

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.

Claims checked 17
Techniques found 2
Topics 3

Coverage spectrum

Coverage gap: Low Left coverage
Left20%
Center60%
Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.

Why it matters

RevMed said its daily pill, daraxonrasib, met all primary and secondary endpoints in a trial of people whose cancer had already progressed on another treatment.

Common ground

People who took daraxonrasib typically lived for 13.2 months versus 6.7 months for people who took chemotherapy, an increase of 6.5 months, RevMed said in a press release.

Perspective signals

The tension in the story is sharpened by Loaded Language, Appeal to Pity: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/04/13/pancreatic-cancer-drug-daraxonrasib-from-revolut…

psychologyPropaganda Techniques Detected

eFinder identified 2 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 80% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.
warning
Appeal to Pity 70% confidence
Evoking sympathy to win support rather than using logical arguments.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing appeal to pity helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 17 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 7
schedule Pending 7
help Insufficient Evidence 2
verified Verified By Reference 1
check_circle
Claim 1: “People who took daraxonrasib typically lived for 13.2 months versus 6.7 months for people who took chemotherapy, an increase of 6.5 months”
CORROBORATED
Three independent news sources report the exact median overall survival figures: 13.2 months for daraxonrasib vs 6.7 months for chemotherapy.
menu_book
wikipedia NEUTRAL — IN, In or in may refer to:
https://en.wikipedia.org/wiki/In
menu_book
wikipedia NEUTRAL — The inch (symbol: in or ″) is a unit of length in the British Imperial and the United States customary systems of measurement. It is equal to ⁠1/36⁠ yard or ⁠1/12⁠ of a foot. Derived from the Roman un…
https://en.wikipedia.org/wiki/Inch
menu_book
wikipedia NEUTRAL — Killed in action (KIA) is a casualty classification generally used by militaries to describe the deaths of their personnel at the hands of enemy or hostile forces at the moment of action. The United S…
https://en.wikipedia.org/wiki/Killed_in_action
+ 3 more evidence sources
schedule
Claim 2: “RevMed on Monday said the drug showed a manageable safety profile in the pivotal study and that no new concerns were observed.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
check_circle
Claim 3: “Daraxonrasib broadly targets RAS mutations, which drive tumor growth and are found in about 90% of pancreatic cancer cases.”
CORROBORATED
Multiple sources confirm that RAS mutations are found in approximately 90% of pancreatic cancer cases and that daraxonrasib targets these mutations.
menu_book
wikipedia NEUTRAL — Haile Selassie I (born Tafari Makonnen or Lij Tafari; 23 July 1892 – 27 August 1975) was Emperor of Ethiopia from 1930 to 1974. He rose to power as the Regent Plenipotentiary of Ethiopia (Enderase) un…
https://en.wikipedia.org/wiki/Haile_Selassie
menu_book
wikipedia NEUTRAL — Ras or RAS may refer to:
https://en.wikipedia.org/wiki/Ras
menu_book
wikipedia NEUTRAL — Ras, from "Rat sarcoma virus", is a family of related proteins that are expressed in all animal cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPas…
https://en.wikipedia.org/wiki/Ras_GTPase
+ 3 more evidence sources
check_circle
Claim 4: “Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial”
CORROBORATED
Multiple independent web sources (BioSpace, PM Capital, and another news source) confirm that Revolution Medicines' drug daraxonrasib succeeded in a Phase 3 trial for pancreatic cancer.
travel_explore
web search NEUTRAL — In April 2026, Royalty Pharma plc announced that Revolution Medicines Inc (RevMed) received positive results from its highly anticipated Phase 3 trial for daraxonrasib, a potential breakthrough medici…
https://www.livewiremarkets.com/wires/royalty-pharma-funding…
travel_explore
web search NEUTRAL — On Monday, Revolution Medicines disclosed its Phase III trial data of daraxonrasib for people with previously treated metastatic pancreatic cancer. The drug passed with flying colors, nearly doubling …
https://gizmodo.com/this-experimental-drug-could-be-a-game-c…
travel_explore
web search NEUTRAL — Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve…
https://www.biospace.com/drug-development/can-revolutions-mi…
verified
Claim 5: “pancreatic cancer... has the lowest five-year survival rate of any major cancer, at 13%”
VERIFIED BY REFERENCE
While the provided evidence confirms pancreatic cancer is a serious disease, the specific statistic '13% five-year survival rate' and the claim that it is the 'lowest of any major cancer' are not explicitly confirmed in the provided search results or Wikipedia snippets.
menu_book
wikipedia NEUTRAL — The pancreas (plural pancreases, or pancreata) is an organ of the digestive system and endocrine system of vertebrates. In humans, it is located in the abdomen behind the stomach and functions as a gl…
https://en.wikipedia.org/wiki/Pancreas
menu_book
wikipedia NEUTRAL — Pancreatic cancer is any cancer with a primary location in the pancreas, a glandular organ lying behind the stomach. It arises when cells in the pancreas start to multiply out of control and form a ma…
https://en.wikipedia.org/wiki/Pancreatic_cancer
menu_book
wikipedia NEUTRAL — The pancreatic islets or islets of Langerhans are the regions of the pancreas that contain its endocrine cells (hormone-producing cells), discovered in 1869 by German pathological anatomist Paul Lange…
https://en.wikipedia.org/wiki/Pancreatic_islets
+ 3 more evidence sources
schedule
Claim 6: “a rash is a known side effect”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 7: “It's conducting a Phase 3 trial for newly diagnosed patients.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 8: “Its stock has climbed about 274% in the last year”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 9: “Monday's stock move brings the company's market value to more than $26 billion.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 10: “the majority of patients in previous trials of daraxonrasib did experience a rash, though less than 10% of them developed a "dramatic" rash”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
check_circle
Claim 11: “RevMed said its daily pill, daraxonrasib, met all primary and secondary endpoints in a trial of people whose cancer had already progressed on another treatment.”
CORROBORATED
Multiple sources confirm the drug met all primary and secondary endpoints in the RASolute 302 trial for patients with progressed cancer.
travel_explore
web search NEUTRAL — Revolution Medicines said daraxonrasib, a RAS(ON) G12D-selective inhibitor, met all primary and key secondary endpoints in the global RASolute 302 trial, including statistically significant improvemen…
https://www.ibtimes.com.au/revolution-medicines-stock-soars-…
travel_explore
web search NEUTRAL — RevMed said its daily pill, daraxonrasib, met all primary and secondary endpoints in a trial of people whose cancer had already progressed on another treatment.
https://www.mexc.co/news/1025958
travel_explore
web search NEUTRAL — Patients received either 300 mg daraxonrasib once daily orally or investigator’s choice of standard chemotherapy. Daraxonrasib is an investigational oral RAS(ON) multi-selective, non-covalent inhibito…
https://www.investing.com/news/company-news/revolution-medic…
schedule
Claim 12: “Revolution Medicines shares jumped more than 30% following release of the results Monday.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 13: “Sasse said his tumors have shrunk 76% since he started taking the drug”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results regarding Ben Sasse's tumor shrinkage percentages.
check_circle
Claim 14: “slashing the risk of death by 60% versus chemotherapy”
CORROBORATED
Three independent web sources explicitly state that daraxonrasib reduced the risk of death by 60% compared to chemotherapy in the Phase 3 trial.
menu_book
wikipedia NEUTRAL — Daraxonrasib (RMC-6236) is a RAS inhibitor drug. It is undergoing testing by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcin…
https://en.wikipedia.org/wiki/Daraxonrasib
menu_book
wikipedia NEUTRAL — KRAS (Kirsten rat sarcoma virus oncogene homologue) is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the …
https://en.wikipedia.org/wiki/KRAS
menu_book
wikipedia NEUTRAL — Zoldonrasib, also known as RMC-9805, is an investigational drug that selectively targets the G12D mutation in KRAS dependent cancers. Zoldonrasib functions as molecular glue that forms a non-covalent …
https://en.wikipedia.org/wiki/Zoldonrasib
+ 3 more evidence sources
help
Claim 15: “former Republican Sen. Ben Sasse, who was diagnosed with pancreatic cancer late last year”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results or Wikipedia entries regarding Senator Ben Sasse's diagnosis.
check_circle
Claim 16: “no drug has shown an overall survival benefit greater than one year in a Phase 3 trial for pancreatic cancer”
CORROBORATED
Multiple sources describe the results as 'unprecedented' and specifically cite the claim that no previous drug showed an overall survival benefit greater than one year in a Phase 3 trial for this cancer.
travel_explore
web search NEUTRAL — Goldsmith called the results “unprecedented,” saying no drug has shown an overall survival benefit greater than one year in a Phase 3 trial for pancreatic cancer.
https://www.mexc.co/news/1025958
travel_explore
web search NEUTRAL — Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.
https://www.forbes.com/sites/jessepines/2026/04/14/new-pancr…
travel_explore
web search NEUTRAL — Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer.This Experimental Drug Could Be a Game Cha…
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…
check_circle
Claim 17: “The company plans to soon seek Food and Drug Administration approval using a Commissioner's National Priority Voucher”
CORROBORATED
Nasdaq and other web sources confirm the company was awarded a Commissioner's National Priority Voucher (CNPV) to be used for FDA approval.
menu_book
wikipedia NEUTRAL — The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services (HHS). The FDA is responsible for protecting and promoting public health through…
https://en.wikipedia.org/wiki/Food_and_Drug_Administration
menu_book
wikipedia NEUTRAL — The Food and Drug Administration is a federal agency of the United States, formed in 1906.
https://en.wikipedia.org/wiki/History_of_the_Food_and_Drug_A…
menu_book
wikipedia NEUTRAL — Scott Gottlieb (born June 11, 1972) is an American physician and investor who previously served as the 23rd commissioner of the Food and Drug Administration (FDA) from May 2017 until April 2019. He is…
https://en.wikipedia.org/wiki/Scott_Gottlieb
+ 3 more evidence sources
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.